SAN DIEGO, Sept. 21 /PRNewswire/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it has reestablished efforts to advance the Aethlon Hemopurifier® within U.S. Government programs that support the development and purchase of treatment countermeasures against bioterror threats. The Aethlon Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. Based on studies conducted by government and non-government research organizations, Aethlon believes the Hemopurifier® represents the most advanced and perhaps the only true broad-spectrum countermeasure against viral threats most likely to be weaponized against civilian and military populations.
Therapeutics able to target multiple bioterror threats have become a focal point of the U.S. Health and Human Services Department (HHS) and dual-use therapies such as the Hemopurifier®, that also have commercial applications against established disease conditions such as hepatitis-C virus (HCV) and cancer, are no longer precluded from consideration to be supported by government programs.
"Revamped government policies expand the opportunity for our Hemopurifier® in the United States and improve our potential access to non-dilutive capital resources, which are not capped by the public market value of our organization," stated Aethlon Chairman and CEO, Jim Joyce. "We now plan to upda